Clinical trial · Interventional
Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy
Peking University People's Hospital
NCT06942377CI-TRIAL-00091870not yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the treatment efficacy of Progesterone Therapeutic Regimen Plus Amlodipine in patients with early endometrial carcinoma (EEC) for conservative treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Amlodipine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Participant Group
- description
- Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or mirena +GnRHa 3.75mg subcutaneous injection monthly)
- type
- EXPERIMENTAL
- label
- Amlodipine Intervention
- description
- Progesterone regimen (oral medroxyprogesterone acetate tablet 250mg-500mg/ day or Mirena +GnRHa3.75mg subcutaneous injection monthly) combined with Amlodipine 5mg/day. If the patient's blood pressure is higher than 140/90mmHg at 5mg/d, the dose of amlodipine can be increased to 10mg/day
- interventionNames
- Drug: Amlodipine
Primary outcomes (1)
- measure
- Pathological cumulative complete response rate after 6 months treatment
- timeFrame
- Day 1:take medication orally every day；Every three months, undergo hysteroscopy to obtain endometrium for HE and IHC of ER/PR; assessed up to 6-7 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: 1. Pathological diagnosis of endometrial adenocarcinoma G1-2 of the endometrium 2. If the pathology is endometrial cancer, MRI or ultrasound confirms that the lesion is limited to the endometrium or invading the muscle\<1/2, that is, FIGO (2009) stage IA 3. Age ≤ 45 years old 4. Require those who wish to retain their reproductive function to sign informed consent 5. No serious internal medicine complications (severe liver and kidney dysfunction) 6. No contraindications for progesterone treatment or pregnancy 7. Has not experienced hypotension more than three times in the past six months and can be regularly monitored for blood pressure 8. Imaging shows no evidence of distant metastasis 9. A. Initial treatment patients: have not used any protective treatment drugs (progestogens, GNRH-a); B. One course of treatment (12 weeks) with incomplete remission of the lesion (partial remission, persistent or progressive lesion); C. Two courses of treatment (24 weeks) with incomplete remission (partial remission, persistent or progressive lesions); Exclusion Criteria: 1. Tumor invasion of muscle layer\>1/2, FIGO (2009) stage IB or above 2. Tumor differentiation into G3 or non endometrioid adenocarcinoma 3. Merge malignant tumors from other parts 4. Individuals with contraindications to conservative treatment or medication use 5. Patients known to have experienced hypotension 6. Patients who have taken other types of antihypertensive drugs regularly in the past
References
Publications (0)
Data not yet available
No reference posted for this study.